R&D News | pharmaphorum

News

Roche ducks out of AC Immune Alzheimer's antibody alliance

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibo

News

Trial data raises questions about Imfinzi in liver cancer

AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects.

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

News

CG Oncology lines up $180m IPO and a $1bn valuation

CG Oncology is the latest biotech to take a look at a share listing in the US, aiming to raise around $180 million in the process, in another sign of a possible recovery i

News

BridgeBio raises $1.25bn, and other biotech financings

Our round-up of recent biotech financings is headed by a massive $1.25 billion round for genetic medicines specialist BridgeBio Pharma, with smaller rounds for Tr1X, Coman

News

DISCO dances out of the shadows with €20m for ‘surfaceome’

Germany has a new biotech, DISCO Pharmaceuticals, which has announced its presence with €20 million (around $22 million) in seed financing that will be used to advance its

Roche ducks out of AC Immune Alzheimer's antibody alliance

Trial data raises questions about Imfinzi in liver cancer

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

CG Oncology lines up $180m IPO and a $1bn valuation

BridgeBio raises $1.25bn, and other biotech financings

DISCO dances out of the shadows with €20m for ‘surfaceome’

Boehringer forges $7bn alliance with China's SBP Group

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks